Chemed Corp. — 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. Although the request identifies Q4 2012, this is an annual filing, not a standalone quarterly report. Chemed operates through VITAS, a hospice and palliative-care provider, and Roto-Rooter, a plumbing and drain-cleaning services business.
Financial position and performance
- The filing text provided does not include the consolidated income statement, balance sheet, or cash-flow statement; those statements and management’s discussion are incorporated from the 2012 Annual Report. Accordingly, revenue, earnings, margins, operating cash flow, cash balances, and detailed liquidity figures are not clear from this text.
- At December 31, 2012, Chemed had no variable-rate debt outstanding. Long-term debt had a carrying value of $174.9 million and an estimated market value of $197.9 million. The company had a $350 million revolving credit facility; a new amended and restated credit agreement was entered into on January 18, 2013.
- Chemed’s 1.875% convertible senior notes were due in 2014. The filing identifies potential dilution tied to convertible debt as a risk but does not provide the potential share count in the supplied text.
- Cash returns to shareholders included quarterly dividends of $0.16, $0.16, $0.18, and $0.18 per share in 2012, versus $0.14, $0.14, $0.16, and $0.16 in 2011. Chemed repurchased 723,472 shares in Q4 2012 at a weighted-average price of $67.43; $14.8 million remained under the repurchase program at year-end.
Material changes and operating context
- VITAS depends heavily on public reimbursement: approximately 90% of its revenue was from Medicare, and more than 90% of its net patient service revenue was from Medicare and Medicaid. Medicaid represented 5% of VITAS revenue in 2012.
- VITAS’s per-diem reimbursement model makes profitability sensitive to care costs, patient mix, reimbursement rates, and annual payment caps. Approximately 21% of VITAS days of care were provided to nursing-home residents.
- Roto-Rooter’s results are weather-sensitive: above-average precipitation or below-freezing temperatures generally benefit operations. VITAS’s Florida activity typically benefits from seasonal retiree migration.
- The filing text does not provide a clear numerical comparison of 2012 versus 2011 consolidated or segment revenue, profit, margins, or cash flow.
Risks, contingencies, and unusual items
- VITAS investigations and claims: The filing describes multiple ongoing government investigations and subpoenas concerning hospice eligibility, billing, patient records, and continuous-care claims, as well as related False Claims Act qui tam suits. Some complaints had not been served; government authorities had declined to intervene in certain cases while continuing investigations. Chemed said investigation-compliance costs were not material for the periods presented, but noted possible defense costs, management distraction, publicity, recoupments, and other adverse outcomes.
- Other litigation: A securities class action relating to alleged VITAS patient-enrollment and billing practices was pending, with defendants seeking dismissal. In a Roto-Rooter wage-and-hour case, the court dismissed claims against Chemed and narrowed parts of the case in February 2013; Roto-Rooter continued to contest remaining claims. A VITAS California employment class action also remained in dispute.
- Environmental exposure: Chemed recorded a $1.7 million accrual for DuBois-related environmental cleanup costs and was contingently liable for up to an additional $14.9 million. Management did not consider payment of the additional amount probable and recorded no provision for it.
- Regulatory and operating risks: VITAS faces Medicare/Medicaid rate and eligibility changes, claim audits, licensing and certification requirements, and risks involving referral relationships, staffing shortages, and nursing costs. Roto-Rooter faces fragmented competition, licensing and franchise regulation, and difficulty attracting skilled employees.
- Debt and capital allocation: Debt covenants may limit borrowing, acquisitions, capital spending, and other actions; a covenant default could accelerate repayment. Future dividends depend on earnings, financial condition, and covenant compliance.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting occurred during Q4 2012. The filing provides no specific earnings or revenue guidance.
Key facts for investors to verify
- Review the incorporated 2012 Annual Report for audited revenue, earnings, margins, cash flows, segment results, cash and debt balances, and management’s year-over-year analysis.
- Track the status, potential financial exposure, and accounting treatment of VITAS investigations, subpoenas, and related litigation.
- Confirm the terms and capacity of the January 2013 credit agreement, covenant headroom, and the treatment or conversion terms of the 2014 convertible notes.
- Assess VITAS’s reimbursement exposure, Medicare cap risk, audit reserves, and ability to control labor and care-delivery costs.
- Monitor environmental remediation estimates and the remaining share-repurchase authorization alongside dividend and capital-allocation plans.